Menthol-Flavored E-Cigarettes for Vaping
Trial Summary
What is the purpose of this trial?
The use of electronic nicotine delivery systems (ENDS; e-cigarettes) has reached epidemic levels among young people in the United States (US). ENDS heat and vaporize a nicotine-containing liquid to produce an inhalable aerosol mist. While generally considered less harmful than combustible cigarettes, ENDS use exposes users to dependence-producing nicotine and respiratory and cardiovascular toxicants such as aldehydes. Flavor is a major factor in getting young people to use ENDS, thus limiting flavors to menthol and tobacco for prefilled cartridge ENDS "pod mods" was the first major action taken by the FDA to reduce the spread of ENDS among young people. Menthol flavor, however, can present a potential risk given its increasing popularity among young people in the US, and its puffing and nicotine-enhancing properties. Yet, the extent of menthol's ability to affect users' experience and puffing patterns, and how these affect dependence, exposure to toxicants, and clinical outcomes continue to be understudied. Such evidence will be critical to the FDA's ability to set further regulatory standards to reduce ENDS potential harm. The investigators will conduct a 2x2 (pre-post x menthol vs. tobacco flavor) crossover clinical lab study. The investigator will recruit current/past month ENDS users (n=250, 21-35 yrs), who will attend two sessions and use their ENDS once with menthol and once with tobacco flavors. The proposed studies will answer two key regulatory questions consistent with FDA's focus on the role of flavor in tobacco products' addiction and toxicity; 1) compared to tobacco flavor, does menthol carry additional risk by enhancing puffing, abuse liability, and toxicant exposure in ENDS users, and; 2) is this effect more pronounced among high dependence compared to other users. Other outcomes such as harm perception, satisfaction, clinical responses, intention to use or quit, and group comparisons such as according to race, and sex will allow the FDA a comprehensive assessment of the pros and cons of regulating mentholated ENDS for different segments of the society. Such evidence will help advance FDA regulatory policies with the potential to reduce ENDS harm.
Will I have to stop taking my current medications?
The trial excludes individuals who regularly use prescription medications (other than vitamins or birth control), so you may need to stop taking your current medications to participate.
What data supports the effectiveness of menthol-flavored e-cigarettes as a treatment?
Is there any safety information available for menthol-flavored e-cigarettes?
How is the menthol-flavored e-cigarette treatment different from other treatments for vaping?
Menthol-flavored e-cigarettes are unique because they provide a cooling sensation that enhances their appeal, especially among youth, and may encourage the transition from traditional smoking to vaping. Unlike other treatments, they use menthol and synthetic cooling agents to create a pleasant sensory experience without the characteristic minty odor.23457
Research Team
Wasim Maziak, PhD, MD
Principal Investigator
Florida International University
Eligibility Criteria
This trial is for healthy adults aged 21-35 who use e-cigarettes at least occasionally in the past month. Participants must not be pregnant, breastfeeding, or using other tobacco products regularly. They should have no chronic diseases, psychiatric conditions, cardiovascular issues, or regular medication use (except vitamins/birth control).Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants attend two lab sessions to use menthol and tobacco-flavored e-cigarettes for up to 60 minutes each
Follow-up
Participants are monitored for changes in nicotine levels, respiratory function, and other clinical outcomes
Treatment Details
Interventions
- Menthol-flavored e-cigarette
- Tobacco-flavored e-cigarette
Menthol-flavored e-cigarette is already approved in United States, European Union, Canada, Japan, China for the following indications:
- None (regulated as a tobacco product)
- None (regulated as a tobacco product)
- None (regulated as a tobacco product)
- None (regulated as a tobacco product)
- None (regulated as a tobacco product)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Florida International University
Lead Sponsor